Cartesian Therapeutics Announces New Employment Inducement Grant
RNAC granted an inducement option on 50,000 shares to one new hire at $6.34, vesting over four years.
What this release says
Cartesian Therapeutics granted a stock option to one newly hired employee as an inducement to join the company. The option covers 50,000 shares at an exercise price equal to the closing price on the grant date, so it gives the employee value only if the stock rises above that level. For a current shareholder this is a small, routine grant that adds a modest amount of potential future dilution.
Key figures
- Shares under option
- 50,000 shares
- Exercise price
- $6.34
- Grant date
- November 2, 2026
- Initial vesting
- 25% on November 2, 2027
- Full vesting date
- November 2, 2030
- Option term
- Ten years
Positive for shareholders
- The exercise price matches the closing price on the grant date, so the employee only benefits if the shares appreciate.
Negative for shareholders
- The option adds potential future dilution to existing shareholders if it is exercised.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Employment inducement award:
- A stock-based award a company grants to a new hire as an incentive to accept a job, granted outside its general shareholder-approved plans under Nasdaq rules.
- Stock option:
- A right to buy company shares at a set price within a set period, which has value only if the share price rises above that price.
- Vesting:
- The schedule over which an employee earns the right to exercise an award, here 25% after one year and monthly after that.
FAQ
How many shares did Cartesian Therapeutics grant in this inducement award?
The company granted one new employee an option to purchase 50,000 shares of its common stock. The option was granted on November 2, 2026.
At what price can the employee buy the shares under this option?
The exercise price is $6.34, which the release describes as the closing trading price on the Nasdaq Global Market on the grant date.
When does the option vest?
The option vests as to 25% on November 2, 2027, then in thirty-six equal monthly installments, becoming fully vested on November 2, 2030.
Historical context for RNAC
Across the 22 sessions after earlier RNAC headlines, the stock closed higher 15 times and lower 7 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RNAC | SPY |
|---|---|---|---|
| Oct 2, 2026 | Cartesian Therapeutics Announces New Employment Inducement Grants | +1.9% | +0.7% |
| Sep 29, 2026 | Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis | +0.4% | -0.2% |
| Sep 8, 2026 | Cartesian Therapeutics Announces New Employment Inducement Grants | -3.5% | -0.5% |
| Sep 3, 2026 | Cartesian Therapeutics to Participate in Upcoming Investor Conferences | +0.4% | +1.0% |
| Aug 7, 2026 | Cartesian Therapeutics Announces New Employment Inducement Grants | +1.0% | +0.6% |
| Aug 6, 2026 | Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | +4.9% | -0.2% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2016
Follow RNAC and get a push notification the moment its next story breaks.